Clinical Trials
31 trialsNK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma
National Institutes of Health Clinical Center (CC)
SABRE
Children's National Research Institute
Engineered Neuroblastoma Cellular Immunotherapy (ENCIT)-01
Seattle Children's Hospital
B7-H3-Specific Chimeric Antigen Receptor Autologous T-Cell Therapy for Pediatric Patients With Solid Tumors (3CAR)
St. Jude Children's Research Hospital
Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial
National Cancer Institute (NCI)
MRG003
Sun Yat-sen University
Flavored, Oral Irinotecan VAL-413 (OrotecanĀ®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors
Stanford University
Indocyanine Green (ICG) Guided Tumor Resection
St. Jude Children's Research Hospital
NEUROBLU 02
Institut Claudius Regaud
MiniVan
University Hospital Southampton NHS Foundation Trust
B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults
Seattle Children's Hospital
PEACH
University of Florida
MAGNETO
University College, London
VEGAS
Baylor College of Medicine
A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma
Eli Lilly and Company
NYMC195
New York Medical College
N2000-01: Double Infusion of Iodine I 131 Metaiodobenzylguanidine Followed by Autologous Stem Cell Transplantation
New Approaches to Neuroblastoma Therapy Consortium
N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-04: Fenretinide LXS in Treating Patients With Recurrent, Refractory, or Persistent Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
N2004-06: Irinotecan and Vincristine With 131I-MIBG Therapy for Resistant/Relapsed High-Risk Neuroblastoma
New Approaches to Neuroblastoma Therapy Consortium
IV Fenretinide
New Approaches to Neuroblastoma Therapy Consortium
Lenalidomide and Dinutuximab With or Without Isotretinoin in Treating Younger Patients With Refractory or Recurrent Neuroblastoma
National Cancer Institute (NCI)
ThINKK-01
St. Justine's Hospital
GRAIN
Baylor College of Medicine
Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma
UNC Lineberger Comprehensive Cancer Center
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
National Institutes of Health Clinical Center (CC)
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells
New Approaches to Neuroblastoma Therapy Consortium
CLOVER-2
Cellectar Biosciences, Inc.